Involving A Modified Enzyme (e.g., Abzyme, Recombinant, Chemically Altered, Etc.) Patents (Class 435/7.6)
-
Patent number: 6406862Abstract: A C-reactive protein concentration level test and kit for on-site determination of C-reactive protein levels in biological samples is disclosed.Type: GrantFiled: October 6, 1999Date of Patent: June 18, 2002Assignee: The United States of America as represented by the Secretary of the ArmyInventor: Teresa Krakauer
-
Patent number: 6365358Abstract: The invention provides a human ubiquitin-like conjugating protein (UBCLE) and polynucleotides which identify and encode UBCLE. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of UBCLE.Type: GrantFiled: June 9, 1999Date of Patent: April 2, 2002Assignee: Incyte Genomics, Inc.Inventors: Jennifer L. Hillman, Purvi Shah, Neil C. Corley
-
Publication number: 20020034797Abstract: Combinatorial libraries of polyketides can be obtained by suitable manipulation of a host modular polyketide synthase gene cluster such as that which encodes the PKS for erythromycin. The combinatorial library is useful as a source of pharmaceutically active compounds.Type: ApplicationFiled: April 30, 1997Publication date: March 21, 2002Inventors: CHAITAN KHOSLA, GARY ASHLEY, HONG FU, CAMILLA M. KAO, ROBERT MCDANIEL
-
Patent number: 6342365Abstract: Substantially pure glycosidases capable for cleaving selected glycosidic bonds have been described including glycosidases isolated from Xanthomonas and recombinant glycosidases. Substrate specificity of isolated enzymes have been identified for GlcNac&bgr;1-X, Gal&agr;1-3R, Gal&agr;1-6R, Gal&bgr;1-3R, Fuc&agr;1-2R, Fuc&agr;1-3R, Fuc&agr;1-4R, Man&agr;1-2R, Man&agr;1-3R, Man&agr;1-6R, Man&bgr;1-4R, Xyl&bgr;1-2R, Glc&bgr;1-4R, and Gal&bgr;1-4R providing improved capability for selectively cleaving a glycosidic linkage in a carbohydrate substrate and for forming modified carbohydrates.Type: GrantFiled: February 24, 1999Date of Patent: January 29, 2002Assignee: New England Biolabs, Inc.Inventors: Sharon T. Wong-Madden, Ellen P. Guthrie, David Landry, Christopher H. Taron, Chudi Guan, Phillips W. Robbins
-
Patent number: 6333154Abstract: A signal amplification system comprises a bacterial multi-hybrid system, and more preferably a two-hybrid system, of at least two chimeric polypeptides containing a first chimeric polypeptide corresponding to a first fragment of an enzyme and a second chimeric polypeptide corresponding to a second fragment of an enzyme or a modulating substance capable of activating said enzyme. The first fragment is fused to a molecule of interest and the second fragment or the modulating substance is fused to a target ligand. The activity of the enzyme is restored by the in vivo interaction between the molecule of interest and the target ligand. Signal amplification is generated and, for example, triggers transcriptional activation. The signal amplification system is useful in a method of selecting a molecule of interest, which is capable of binding to target ligand, wherein the interaction between the molecule of interest and the target ligand is detected with the signal amplification system as a kit therefor.Type: GrantFiled: December 1, 1998Date of Patent: December 25, 2001Assignee: Institut PasteurInventors: Daniel Ladant, Gouzel Karimova, Agnes Ullmann
-
Patent number: 6329160Abstract: A genetic construct for use in a biosensor comprising: (a) a first nucleic acid molecule including a sequence encoding a reporter molecule having a detectable activity; and (b) a second nucleic acid molecule including a sequence encoding an enzyme which produces a substrate for the reporter molecule, the first sequence being under the control of a first inducible promoter and the second sequence being under the control of a second inducible promoter. A biosensor for measuring an environmental signal comprising a cell including the genetic construct and a means for measuring the activity of the reporter molecule in the cell when the cell has been exposed to the environmental signal.Type: GrantFiled: September 7, 1999Date of Patent: December 11, 2001Assignee: CRC for Waste Management and Pollution Control LimitedInventors: Rene Schneider, Tony Vancov, Karen Jury
-
Patent number: 6296853Abstract: E6-BP polypeptide, nucleic acids encoding E6-BP polypeptides, and uses thereof.Type: GrantFiled: August 26, 1999Date of Patent: October 2, 2001Assignee: New England Medical Center Hospitals, Inc.Inventors: Elliot J. Androphy, Jason J. Chen
-
Patent number: 6297013Abstract: This invention provides plasmids that are useful in detecting and determining the DNA-binding activity of sequence-specific DNA-binding molecules. The invention further provides plasmids that are useful in detecting and determining the activity of KNA polymerases in initiating transcription. In particular, the invention relates to plasmids that contain unique restriction sites and cognate nucleotide recognition sequences for sequence-specific DNA-binding molecules. Also provided are methods for using the plasmids disclosed herein.Type: GrantFiled: June 24, 1999Date of Patent: October 2, 2001Assignee: Dnab Diagnostics Inc.Inventors: Antony R. Morgan, Alberto Severini
-
Patent number: 6290966Abstract: Disclosed are novel recombinant mutant strains of mycobacteria that are deficient for the synthesis or transport of dimycoserosalphthiocerol (“DIM”). The present invention also provides a method of producing a recombinant mutant mycobacterium that is deficient for the synthesis or transport of DIM, comprising mutating a nucleic acid responsible for the synthesis or transport of dimycoserosalphthiocerol, including a nucleic acid comprising the promoter for the pps operon, fadD28 or mmpL7. The present invention also provides a vaccine comprising a DIM mutant mycobacterium of the present invention, as well as a method for the treatment or prevention of tuberculosis in a subject using the vaccine.Type: GrantFiled: July 9, 1999Date of Patent: September 18, 2001Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Jeffery S. Cox, William R. Jacobs, Jr.
-
Patent number: 6287785Abstract: An improved homogeneous enzyme immunoassay process for quantitatively analyzing an antigen by determining the change in the enzymatic activity caused by a reaction between the antigen and an enzyme-labeled antibody. The antigen is reacted with an enzyme-labeled antibody, followed by the reaction with a second antibody capable of recognizing and binding to a different epitope and then with a third antibody capable of recognizing and binding to the second antibody. The enzymatic activity of the labeling enzyme is determined by a water-insoluble substrate. Using the water-insoluble substrate, steric hindrance is enhanced. A highly-sensitive analysis can be carried out by a simple operation even when the antigen has a molecular weight falling within an intermediate range, for example, a range of M.W. 10,000 to 70,000.Type: GrantFiled: January 20, 2000Date of Patent: September 11, 2001Assignee: Fuji Photo Film Co., Ltd.Inventors: Hiroshi Shinoki, Osamu Seshimoto
-
Publication number: 20010018200Abstract: The present invention relates to a chemically modified mutant protein including a cysteine residue substituted for a residue other than cysteine in a precursor protein, the substituted cysteine residue being subsequently modified by reacting the cysteine residue with a glycosylated thiosulfonate. Also, a method of producing the chemically modified mutant protein is provided. The present invention also relates to a glycosylated methanethiosulfonate. Another aspect of the present invention is a method of modifying the functional characteristics of a protein including providing a protein and reacting the protein with a glycosylated methanethiosulfonate reagent under conditions effective to produce a glycoprotein with altered functional characteristics as compared to the protein. In addition, the present invention relates to methods of determining the structure-function relationships of chemically modified mutant proteins.Type: ApplicationFiled: July 2, 1999Publication date: August 30, 2001Inventors: BRYAN J. JONES, BENJAMIN G. DAVIS
-
Patent number: 6277586Abstract: The invention provides cDNA molecules comprising a part of the cDNA sequence of GAD65 which encode at least one epitope for autoantibodies to GAD65. The invention also provides cloning vehicles capable of replication and expression comprising cDNA molecules coding for GAD65. The invention further provides for hosts transformed with a vehicle having a cDNA molecule coding for GAD65. In another embodiment, the invention provides for the detection of autoantibodies to GAD65 using the GAD65 polypeptides coded for by the cDNA molecules of the invention.Type: GrantFiled: August 11, 1999Date of Patent: August 21, 2001Assignee: Regents of the University of CaliforniaInventors: Allan J. Tobin, Mark G. Erlander, Daniel L. Kaufman
-
Patent number: 6274318Abstract: The invention provides an isolated gene encoding Mch6 as well as functional fragments thereof. Also provided are isolated nucleic acid sequences encoding Mch6 or functional fragments thereof. The gene or nucleic acid sequences can be single or double stranded nucleic acids corresponding to coding or non-coding strands of the Mch6 nucleotide sequences. The invention further provides an isolated Mch6 polypeptide and isolated large and small subunits of the Mch6 polypeptide, including functional fragments thereof.Type: GrantFiled: May 13, 1999Date of Patent: August 14, 2001Assignee: Thomas Jefferson UniversityInventors: Emad S. Alnemri, Teresa Fernandes-Alnemri, Gerald Litwack
-
Patent number: 6268123Abstract: The present invention relates to processes for the direct detection of biochemically functional retroviruses in biological samples. The processes of the invention are characterized by the structure-specific extraction of retrovirus particles and a subsequent analysis and detection of retrovirus-specific enzymatic reactions. The processes of the invention have broad application in the diagnosis of retroviral infection and virological research.Type: GrantFiled: February 28, 1996Date of Patent: July 31, 2001Assignee: Retro-Tech GmbHInventor: Ortwin Faff
-
Patent number: 6262265Abstract: Novel chemical analogs are disclosed for the essential heroin metabolite 6-O-acetyl morphine (6MAM). The analogs optionally can be made to contain protein reactive groups, and can be used to form protein conjugates, fluorescently labeled compounds, and solid-phase adsorbants. The proteins conjugates can be used in turn to raise antibodies reactive with 6MAM and having a low cross-reactivity with the closely related opiates, morphine and codeine. The antibodies can be used in combination with labeled analogs in exquisitely sensitive immunoassays suitable for testing for heroin abuse.Type: GrantFiled: June 18, 1999Date of Patent: July 17, 2001Assignee: Microgenics CorporationInventors: Riaz Rouhani, Gerald F. Sigler
-
Patent number: 6248229Abstract: The invention relates to novel methods and compositions for the detection of analytes using the nuclear reorganization energy, &lgr;, of an electron transfer process.Type: GrantFiled: October 13, 1999Date of Patent: June 19, 2001Assignee: Clinical Micro Sensors, Inc.Inventor: Thomas J. Meade
-
Patent number: 6229001Abstract: The invention relates to the nucleic acid sequence and amino acid sequence of dihydrofolate reductase (DHFR) from mycobacteria and to expression of recombinant DHFR protein. Utilizing the recombinant protein, novel therapies and diagnostic strategies can be developed and selective antimycobacterial compositions can be designed and utilized to treat mycobacterial infections in patients. This invention includes all or portions of novel recombinant nucleic acids encoding DHFR for mycobacteria such as M. avium, to novel recombinant DHFR peptides produced by such sequences, and to vaccines, diagnostic kits, cells and therapies utilizing these peptides and nucleic acid sequences. The present invention relates to methods for using the sequences of the present invention to develop drugs specific to M. avium and other mycobacteria, to identify and sequence corresponding sequences in species other than M. avium, as well as diagnostic and treatment methods incorporating the disclosed sequences and peptides.Type: GrantFiled: December 15, 1997Date of Patent: May 8, 2001Assignee: Southern Research InstituteInventors: William W. Barrow, Sabrina Z. Van Ginkel, Thomas P. Dooley, William J. Suling
-
Patent number: 6221617Abstract: A method and recombinant assay cell for detecting growth hormone releasing hormone (GHRH) in a sample, the method includes exposing a recombinant cell to the sample and measuring transcription of a reporter gene. A suitable recombinant cell includes a reporter gene operatively connected to a cAMP-responsive promoter and a GHRH-responsive protein whose binding to GHRH induces the production of cAMP. GHRH present in an assay sample results in the GHRH-responsive protein activating the production of cAMP, which then activates the c-AMP-responsive promoter to express the reporter protein. The amount of reporter protein produced is quantitatively correlated to the amount of GHRH in the sample. In one embodiment, the protein is a cell surface receptor for GHRH.Type: GrantFiled: December 5, 1997Date of Patent: April 24, 2001Inventors: Julie Heinrich, H. Edward Grotjan, Fred W. Wagner, Yuannan Xia
-
Patent number: 6217864Abstract: A method for in vivo selective targeted degradation of intracellular proteins in situ by inducing in vivo or ex vivo in cells a production of dual-function protein comprising N-terminal domain as well as a C-terminal domain or delivering the dual-function protein. The N-terminal domain of the dual-function protein destabilizes the target protein and directs its degradation when linked to it through a linker between the target protein and between the protein agent of the invention. The protein degradation directing N-terminal domain is a subregion within the first 97 amino acids corresponding to the N-terminus of protein antizyme.Type: GrantFiled: February 2, 1999Date of Patent: April 17, 2001Assignee: The Regents of the University of CaliforniaInventors: Philip Coffino, Xianqiang Li
-
Patent number: 6207396Abstract: To improve the detection of LSD in biological samples, antibodies are raised to LSD conjugated to a protein carrier, preferably through the indole ring. Selected antibodies are matched with an immunoassay reagent in which the LSD is conjugated in the same position to a labeling or separation means. The set of reagents can be used in immunoassays with remarkably little cross-reactivity with potential interfering substances such as chlorpromazine and ergotamine, and a low false-positive rate in a panel of clinical test samples. Also provided is a set of reagents for measuring glucuronide metabolites of LSD by immunoassay, which permits exposure to LSD to be determined over a longer diagnostic window.Type: GrantFiled: February 20, 1998Date of Patent: March 27, 2001Assignee: Microgenics CorporationInventors: Gerald F. Sigler, Riaz Rouhani, David Davoudzadeh, William A. Coty, Jeffrey E. Shindelman, Paul R. Morrill
-
Patent number: 6203986Abstract: A method for visualizing the location and movement of a specific RNA of interest in a living cell, in real time, is disclosed. The method includes the following steps: (a) providing a DNA encoding the RNA, which RNA includes a protein-binding site; (b) providing a nucleic acid encoding a fusion protein, which fusion protein comprises a fluorescent domain and an RNA-binding domain; (c) introducing the DNA encoding the RNA, and the nucleic acid encoding the fusion protein, into a eukaryotic cell so that the DNA encoding the RNA and the nucleic acid encoding the fusion protein are expressed in the cell; and (d) detecting fluorescence outside the nucleus or inside the nucleus of the cell, with the fluorescence being from the fusion protein bound to the RNA. In some embodiments, the fusion protein also includes an intracellular localization domain.Type: GrantFiled: October 22, 1998Date of Patent: March 20, 2001Inventors: Robert H. Singer, Edouard Bertrand
-
Patent number: 6203994Abstract: The invention relates to novel fluorescence-based assays for protein kinases and phosphatases which can be used in high throughput screening. The methods of the invention utilize a competitive immunoassay to determine the amount of substrate that is phosphorylated or dephosphorylated during the course of a kinase or phosphatase reaction to yield a product, as well as the phosphorylating or dephosphorylating activity of a kinase or phosphatase.Type: GrantFiled: December 2, 1998Date of Patent: March 20, 2001Assignee: Pharmacia & Upjohn CompanyInventors: Dennis E. Epps, Charles K. Marschke
-
Patent number: 6194183Abstract: The invention relates to a method of identifying enzymes suitable for use in detergents, especially the selection of specific enzyme variants among a large number of such variants created through random mutagenesis.Type: GrantFiled: February 2, 1998Date of Patent: February 27, 2001Assignee: Novo Nordisk A/SInventors: Peter Markvardsen, Mads Eskelund Bjornvad, Frank Mikkelsen, Borge Diderichsen
-
Patent number: 6190916Abstract: The present invention relates to stable compositions useful as primary standards and calibrators and controls comprising a cardiac troponin I (cTnI) such as native, recombinant, addition and deletion forms thereof, whether or not complexed with other troponin subunits such as TnC and/or TnT, in an inactivated human serum. The compositions are obtained by incubating troponin complexes with human serum. The compositions are characterized by an immunodetectability ratio of epitopes on the N-terminal segment to epitopes on the C-terminal segment substantially equivalent to that of pooled, fresh serum from acute myocardial infarction patients.Type: GrantFiled: June 29, 1999Date of Patent: February 20, 2001Assignee: Spectral Diagnostics, Inc.Inventors: Shigui Liu, Min Yuan Zhang, Qinwei Shi
-
Patent number: 6177241Abstract: This invention provides a method, a reagent, and a kit for detecting herpesvirus-specific IgM antibodies indicative of recent infection while preventing detection of low levels of herpesvirus-specific IgM antibodies present in individuals of low risk. The invention also provides a reagent for use in detecting herpesvirus-specific IgM antibodies indicative of recent infection while preventing detection of low levels of herpesvirus-specific IgM antibodies present in individuals of low risk.Type: GrantFiled: September 22, 1997Date of Patent: January 23, 2001Assignee: Abbott LaboratoriesInventor: Gregory T. Maine
-
Patent number: 6171820Abstract: Disclosed is a rapid and facilitated method of producing from a parental template polynucleotide, a set of mutagenized progeny polynucleotides whereby at each original codon position there is produced at least one substitute codon encoding each of the 20 naturally encoded amino acids. Accordingly, there is also provided a method of producing from a parental template polypeptide, a set of mutagenized progeny polypeptides wherein each of the 20 naturally encoded amino acids is represented at each original amino acid position. The method provided is termed site-saturation mutagenesis, or simply saturation mutagenesis, and can be used in combination with other mutagenization processes, such as, for example, a process wherein two or more related polynucleotides are introduced into a suitable host cell such that a hybrid polynucleotide is generated by recombination and reductive reassortment.Type: GrantFiled: February 4, 1999Date of Patent: January 9, 2001Assignee: Diversa CorporationInventor: Jay M. Short